{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:43Z","timestamp":1787020843204,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer, due to asymptomatic early stages, vague symptoms in later stages, and limited clinical tools. Despite distinct clinicopathologic features, all EOC histotypes typically receive identical primary treatment, and are often studied as a single entity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the proteome of 244 patients and identified differentially abundant proteins (DAPs) with and without stage specificity across histotypes and constructed panels of DAPs to distinguish histotypes in both early and late stages. Survival analysis was performed to find proteins associated with clinical outcomes, and enrichment analysis was conducted to reveal biological processes connected to prognosis and the proteins involved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we find DAPs without (e.g. S100A1, AGR2, CTH) and with (TSPYL, VWA2, GPC6, S100P) stage-specificity for each histotype. Survival analysis revealed histotype- and stage-specific prognostic markers (e.g., EXO3CL2, PPIL6, GYG1, GAPDH), while biological process enrichment highlighted pathways underlying clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings provide novel diagnostic and prognostic biomarker candidates and insights into mechanisms driving EOC progression with histotype- and stage-specificity. This may aid the development of improved clinical tools for detection, patient stratification, and targeted therapies in EOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-026-01984-4","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:07:11Z","timestamp":1769566031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteomic analysis of ovarian carcinoma reveals diagnostic and prognostic biomarkers with histotype- and stage-specificity"],"prefix":"10.1186","volume":"19","author":[{"given":"Lucas","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Ittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Werner","family":"R\u00f6nnerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mateoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Dahm-K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshima Z.","family":"Parris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"5","key":"1984_CR1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","volume":"220","author":"M Sideris","year":"2024","unstructured":"Sideris M, Menon U, Manchanda R. Screening and prevention of ovarian cancer. Med J Aust. 2024;220(5):264\u201374.","journal-title":"Med J Aust"},{"issue":"1","key":"1984_CR2","doi-asserted-by":"crossref","first-page":"e22624","DOI":"10.1002\/jcla.22624","volume":"33","author":"B Kim","year":"2019","unstructured":"Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE, et al. Diagnostic performance of CA 125, HE 4, and risk of ovarian malignancy algorithm for ovarian cancer. J Clin Lab Anal. 2019;33(1):e22624.","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"1984_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"1984_CR4","doi-asserted-by":"crossref","unstructured":"R.L. Pullen Jr, Ovarian cancer, Nursing. 2024;54(6):17\u201328.","DOI":"10.1097\/NSG.0000000000000002"},{"key":"1984_CR5","doi-asserted-by":"crossref","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019;35(2):151\u201356.","DOI":"10.1016\/j.soncn.2019.02.001"},{"issue":"5","key":"1984_CR6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","volume":"35","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430\u201341.","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"1984_CR7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):943\u201364.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"1984_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2020.09.004","volume":"159","author":"C Palmqvist","year":"2020","unstructured":"Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm-K\u00e4hler P. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020;159(2):409\u201317.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1984_CR9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"137","author":"KC Kurnit","year":"2021","unstructured":"Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108\u201321.","journal-title":"Obstet Gynecol"},{"key":"1984_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057.","journal-title":"Cancer Lett"},{"key":"1984_CR11","volume-title":"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: histopathology","author":"MH Rendi","year":"2016","unstructured":"Rendi MH, Garcia RL, Dizon DS. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: histopathology. Available via www. uptodate. com: Published; 2016."},{"issue":"11","key":"1984_CR12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria P-J, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668\u201379.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1984_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237\u201349.","journal-title":"Virchows Arch"},{"issue":"51","key":"1984_CR14","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.1073\/pnas.1712731114","volume":"114","author":"Q Wang","year":"2017","unstructured":"Wang Q, Zhang M, Tomita T, Vogelstein JT, Zhou S, Papadopoulos N, et al. Selected reaction monitoring approach for validating peptide biomarkers. Proc Natl Acad Sci U S A. 2017;114(51):13519\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1984_CR15","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1074\/mcp.RA118.001221","volume":"18","author":"R H\u00fcttenhain","year":"2019","unstructured":"H\u00fcttenhain R, Choi M, de la Fuente LM, Oehl K, Chang C-Y, Zimmermann A-K, et al. A targeted mass spectrometry strategy for developing proteomic biomarkers: a case study of epithelial ovarian cancer. Mol Cell Proteomics. 2019;18(9):1836\u201350.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"1984_CR16","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/s41467-023-43282-3","volume":"14","author":"T-T Gong","year":"2023","unstructured":"Gong T-T, Guo S, Liu F-H, Huo Y-L, Zhang M, Yan S, et al. Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes. Nat Commun. 2023;14(1):7802.","journal-title":"Nat Commun"},{"issue":"1","key":"1984_CR17","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1038\/s41467-024-50786-z","volume":"15","author":"L Qian","year":"2024","unstructured":"Qian L, Zhu J, Xue Z, Zhou Y, Xiang N, Xu H, et al. Proteomic landscape of epithelial ovarian cancer. Nat Commun. 2024;15(1):6462.","journal-title":"Nat Commun"},{"issue":"10","key":"1984_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.15252\/msb.20145625","volume":"10","author":"CS Hughes","year":"2014","unstructured":"Hughes CS, Foehr S, Garfield DA, Furlong EE, Steinmetz LM, Krijgsveld J. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol Syst Biol. 2014;10(10):757.","journal-title":"Mol Syst Biol"},{"issue":"2","key":"1984_CR19","doi-asserted-by":"crossref","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","volume":"1875","author":"M Zhang","year":"2021","unstructured":"Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2021;1875(2):188503.","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"key":"1984_CR20","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.3390\/ijms231912041","volume":"19","author":"R Zhang","year":"2022","unstructured":"Zhang R. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci. 2022;19:12041.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1984_CR21","first-page":"4722","volume":"62","author":"DR Schwartz","year":"2002","unstructured":"Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722\u20139.","journal-title":"Cancer Res"},{"issue":"10","key":"1984_CR22","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.21037\/tcr-24-430","volume":"13","author":"W Jin","year":"2024","unstructured":"Jin W, Hui H, Jiang J, Li B, Deng Z, Tuo X. S100A1 overexpression stimulates cell proliferation and is predictive of poor outcome in ovarian cancer. Transl Cancer Res. 2024;13(10):5265.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"1984_CR23","doi-asserted-by":"crossref","first-page":"e0234152","DOI":"10.1371\/journal.pone.0234152","volume":"15","author":"D Dowarha","year":"2020","unstructured":"Dowarha D, Chou R-H, Yu C. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity. PLoS ONE. 2020;15(6):e0234152.","journal-title":"PLoS ONE"},{"key":"1984_CR24","first-page":"1","volume":"39","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu X-H, Li C, Wu X-X, Chen Y-L, Li W-W, et al. SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K\/AKT signaling pathway. J Exp Clin Cancer Res. 2020;39:1\u201311.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1984_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41419-023-06398-4","volume":"15","author":"X Fu","year":"2024","unstructured":"Fu X, Zhang Q, Wang Z, Xu Y, Dong Q. Crabp2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1\u03b1. Cell Death Dis. 2024;15(1):21.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1984_CR26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3858\/emm.2011.43.2.011","volume":"43","author":"K Park","year":"2011","unstructured":"Park K, Chung YJ, So H, Kim K, Park J, Oh M, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011;43(2):91\u2013100.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1984_CR27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.4934","volume":"243","author":"DR Cochrane","year":"2017","unstructured":"Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, et al. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017;243(1):26\u201336.","journal-title":"J Pathol"},{"key":"1984_CR28","doi-asserted-by":"crossref","first-page":"144458","DOI":"10.1016\/j.gene.2020.144458","volume":"738","author":"P Dausinas","year":"2020","unstructured":"Dausinas P, Pulakanti K, Rao S, Cole JM, Dahl R, Cowden Dahl KD. Arid3a and Arid3b induce stem promoting pathways in ovarian cancer cells. Gene. 2020;738:144458.","journal-title":"Gene"},{"issue":"12","key":"1984_CR29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1089\/dna.2017.3904","volume":"36","author":"L Shao","year":"2017","unstructured":"Shao L, Shen Z, Qian H, Zhou S, Chen Y. Knockdown of miR-629 inhibits ovarian cancer malignant behaviors by targeting testis-specific Y-like protein 5. DNA Cell Biol. 2017;36(12):1108\u201316.","journal-title":"DNA Cell Biol"},{"key":"1984_CR30","doi-asserted-by":"crossref","first-page":"135394","DOI":"10.1016\/j.ijbiomac.2024.135394","volume":"279","author":"Y Tian","year":"2024","unstructured":"Tian Y, Zhao Q, Wu H, Guo J, Wu H. VWA2 protein molecular mechanism predicts colorectal cancer: promoting cell invasion and migration by inhibiting NK cell activation. Int J Biol Macromol. 2024;279:135394.","journal-title":"Int J Biol Macromol"},{"key":"1984_CR31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.abb.2014.02.012","volume":"547","author":"K Fischer","year":"2014","unstructured":"Fischer K, von Br\u00fcnneck A-C, Hornung D, Denkert C, Ufer C, Schiebel H, et al. Differential expression of secretoglobins in normal ovary and in ovarian carcinoma\u2013overexpression of mammaglobin-1 is linked to tumor progression. Arch Biochem Biophys. 2014;547:27\u201336.","journal-title":"Arch Biochem Biophys"},{"key":"1984_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1757-2215-7-26","volume":"7","author":"J Berntsson","year":"2014","unstructured":"Berntsson J, Lundgren S, Nodin B, Uhl\u00e9n M, Gaber A, Jirstr\u00f6m K. Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer. J Ovarian Res. 2014;7:1\u20138.","journal-title":"J Ovarian Res"},{"issue":"3","key":"1984_CR33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/cancers15030893","volume":"15","author":"Y Grobben","year":"2023","unstructured":"Grobben Y, den Ouden JE, Aguado C, van Altena AM, Kraneveld AD, Zaman GJ. Amino acid-metabolizing enzymes in advanced high-grade serous ovarian cancer patients: value of ascites as biomarker source and role for IL4I1 and IDO1. Cancers. 2023;15(3):893.","journal-title":"Cancers"},{"key":"1984_CR34","first-page":"1","volume":"19","author":"H Zhao","year":"2021","unstructured":"Zhao H, Teng Y, Hao W, Li J, Li Z, Chen Q, et al. Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression. J Transl Med. 2021;19:1\u201315.","journal-title":"J Transl Med"},{"issue":"1","key":"1984_CR35","first-page":"712438","volume":"2015","author":"A Karapetsas","year":"2015","unstructured":"Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, et al. Overexpression of GPC6 and TMEM132D in early stage ovarian cancer correlates with CD8+ T-lymphocyte infiltration and increased patient survival. BioMed Res Int. 2015;2015(1):712438.","journal-title":"BioMed Res Int"},{"issue":"2","key":"1984_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.canlet.2015.12.031","volume":"373","author":"M Kang","year":"2016","unstructured":"Kang M, Qin W, Buya M, Dong X, Zheng W, Lu W, et al. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Lett. 2016;373(2):241\u201350.","journal-title":"Cancer Lett"},{"issue":"10","key":"1984_CR37","first-page":"4455","volume":"8","author":"C-Y Chai","year":"2016","unstructured":"Chai C-Y, Zhang Y, Song J, Lin S-C, Sun S, Chang I-W. VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers. Am J Transl Res. 2016;8(10):4455.","journal-title":"Am J Transl Res"},{"key":"1984_CR38","doi-asserted-by":"crossref","unstructured":"Liu S, He Y, Ning X, Xu W, Hu X, Qin L, et al. SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer. Oncogene. 2026;45(2):140\u2013263.","DOI":"10.1038\/s41388-025-03584-w"},{"key":"1984_CR39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fonc.2019.01150","volume":"9","author":"J Graumann","year":"2019","unstructured":"Graumann J, Finkernagel F, Reinartz S, Stief T, Br\u00f6dje D, Renz H, et al. Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma. Front Oncol. 2019;9:1150.","journal-title":"Front Oncol"},{"key":"1984_CR40","doi-asserted-by":"crossref","first-page":"126782","DOI":"10.1016\/j.talanta.2024.126782","volume":"280","author":"W Lyu","year":"2024","unstructured":"Lyu W, Cheng X, Yu Z, Dong R, Sheng Z, Zhang T, et al. Early-stage diagnosis of ovarian cancer via digital immunoassay on a SlipChip. Talanta. 2024;280:126782.","journal-title":"Talanta"},{"issue":"9","key":"1984_CR41","doi-asserted-by":"crossref","first-page":"e1614856","DOI":"10.1080\/2162402X.2019.1614856","volume":"8","author":"F Antony","year":"2019","unstructured":"Antony F, Deantonio C, Cotella D, Soluri MF, Tarasiuk O, Raspagliesi F, et al. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology. 2019;8(9):e1614856.","journal-title":"Oncoimmunology"},{"issue":"8","key":"1984_CR42","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.201412-2226OC","volume":"193","author":"CY Hsu","year":"2016","unstructured":"Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, et al. Huntingtin-interacting protein-1 is an early-stage prognostic biomarker of lung adenocarcinoma and suppresses metastasis via Akt-mediated epithelial-mesenchymal transition. Am J Respir Crit Care Med. 2016;193(8):869\u201380.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1984_CR43","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/life12111730","volume":"12","author":"C Watanabe","year":"2022","unstructured":"Watanabe C, Shibuya H, Ichiyama Y, Okamura E, Tsukiyama-Fujii S, Tsukiyama T, et al. Essential roles of exocyst complex component 3-like 2 on cardiovascular development in mice. Life. 2022;12(11):1730.","journal-title":"Life"},{"key":"1984_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00109-015-1377-9","volume":"94","author":"CE Zois","year":"2016","unstructured":"Zois CE, Harris AL. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. J Mol Med Berl. 2016;94:137\u201354.","journal-title":"J Mol Med Berl"},{"key":"1984_CR45","doi-asserted-by":"crossref","unstructured":"Gao Y, Yu Y, Wu H, Xiao Z, Li J. Mitochondrial ribosomal protein S24 is associated with immunosuppressive microenvironment and cold tumor in lung adenocarcinoma. Heliyon. 2024;10(7):e29171.","DOI":"10.1016\/j.heliyon.2024.e29171"},{"issue":"8","key":"1984_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1159\/000531357","volume":"101","author":"N Liang","year":"2023","unstructured":"Liang N, Zhang X, Zhang L, Jiang M, Bai H, Ding C, et al. Peripheral blood-derived circVPS35L as a potential diagnostic biomarker for non-small cell lung cancer. Oncology. 2023;101(8):527\u201336.","journal-title":"Oncology"},{"issue":"7645","key":"1984_CR47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"C.G.A.R. Network","year":"2017","unstructured":"C.G.A.R. Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378.","journal-title":"Nature"},{"key":"1984_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6890-13-30","volume":"13","author":"E Hjerpe","year":"2013","unstructured":"Hjerpe E, Egyhazi Brage S, Carlson J, Frostvik Stolt M, Schedvins K, Johansson H, et al. Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer. BMC Clin Pathol. 2013;13:1\u20138.","journal-title":"BMC Clin Pathol"},{"issue":"5","key":"1984_CR49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-024-06713-7","volume":"15","author":"J Ji","year":"2024","unstructured":"Ji J, Qian Q, Cheng W, Ye X, Jing A, Ma S, et al. FOXP4-mediated induction of PTK7 activates the Wnt\/\u03b2-catenin pathway and promotes ovarian cancer development. Cell Death Dis. 2024;15(5):332.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1984_CR50","doi-asserted-by":"crossref","first-page":"BSR20204008","DOI":"10.1042\/BSR20204008","volume":"41","author":"T Hua","year":"2021","unstructured":"Hua T, Tian Y-J, Wang R-M, Zhao C-F, Kong Y-H, Tian R-Q, et al. Foxp4-AS1 is a favorable prognostic-related enhancer RNA in ovarian cancer. Biosci Rep. 2021;41(4):BSR20204008.","journal-title":"Biosci Rep"},{"issue":"8","key":"1984_CR51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cac2.12322","volume":"42","author":"HY Cui","year":"2022","unstructured":"Cui HY, Wei W, Qian MR, Tian RF, Fu X, Li HW, et al. PDGFA-associated protein 1 is a novel target of c-Myc and contributes to colorectal cancer initiation and progression. Cancer Commun. 2022;42(8):750\u201367.","journal-title":"Cancer Commun"},{"issue":"10","key":"1984_CR52","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1541-7786.MCR-18-0157","volume":"16","author":"X Zhao","year":"2018","unstructured":"Zhao X, Xie T, Dai T, Zhao W, Li J, Xu R, et al. CHP2 promotes cell proliferation in breast cancer via suppression of FOXO3a. Mol Cancer Res. 2018;16(10):1512\u201322.","journal-title":"Mol Cancer Res"},{"key":"1984_CR53","doi-asserted-by":"crossref","first-page":"155009","DOI":"10.1016\/j.prp.2023.155009","volume":"253","author":"J Dimberg","year":"2024","unstructured":"Dimberg J, Shamoun L, Johansson G, Landerholm K, W\u00e5gs\u00e4ter D. Emerging role and clinical implication of mRNA scavenger decapping enzyme in colorectal cancer. Pathology-Research and Practice. 2024;253:155009.","journal-title":"Pathology-Research and Practice"},{"issue":"5","key":"1984_CR54","doi-asserted-by":"crossref","first-page":"e97059","DOI":"10.1371\/journal.pone.0097059","volume":"9","author":"R Alsiary","year":"2014","unstructured":"Alsiary R, Br\u00fcning-Richardson A, Bond J, Morrison EE, Wilkinson N, Bell SM. Deregulation of microcephalin and ASPM expression are correlated with epithelial ovarian cancer progression. PLoS ONE. 2014;9(5):e97059.","journal-title":"PLoS ONE"},{"issue":"11","key":"1984_CR55","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","volume":"35","author":"J Li","year":"2023","unstructured":"Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, et al. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35(11):2044-2059. e8.","journal-title":"Cell Metab"},{"issue":"8","key":"1984_CR56","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/cancers14081878","volume":"14","author":"J Gao","year":"2022","unstructured":"Gao J, Jung M, Williams RT, Hui D, Russell AJ, Naim AJ, et al. Suppression of the ABCA1 cholesterol transporter impairs the growth and migration of epithelial ovarian cancer. Cancers (Basel). 2022;14(8):1878.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1984_CR57","doi-asserted-by":"crossref","first-page":"e1000387","DOI":"10.1371\/journal.pgen.1000387","volume":"5","author":"E Kotova","year":"2009","unstructured":"Kotova E, Jarnik M, Tulin AV. Poly (ADP-ribose) polymerase 1 is required for protein localization to Cajal body. PLoS Genet. 2009;5(2):e1000387.","journal-title":"PLoS Genet"},{"key":"1984_CR58","doi-asserted-by":"crossref","first-page":"135079","DOI":"10.1016\/j.ijbiomac.2024.135079","volume":"279","author":"H Lv","year":"2024","unstructured":"Lv H, Du Y, Xin P, Zhong Y, Liu Z, Jing Y. Identification of prevention marker associated with DNA replication in ovarian cancer: expression of MCM2 protein and bioinformatics analysis. Int J Biol Macromol. 2024;279:135079.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1984_CR59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol Mech Dis. 2015;10(1):425\u201348.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"11","key":"1984_CR60","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/ijc.27948","volume":"132","author":"G Carbotti","year":"2013","unstructured":"Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2013;132(11):2597\u2013605.","journal-title":"Int J Cancer"},{"issue":"2","key":"1984_CR61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14728214.2015.1036739","volume":"20","author":"AL Jackson","year":"2015","unstructured":"Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 2015;20(2):331\u201346.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"1984_CR62","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cancers15041282","volume":"15","author":"S Oncul","year":"2023","unstructured":"Oncul S, Cho MS. Interactions between platelets and tumor microenvironment components in ovarian cancer and their implications for treatment and clinical outcomes. Cancers (Basel). 2023;15(4):1282.","journal-title":"Cancers (Basel)"},{"issue":"26","key":"1984_CR63","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187(26):7492-7510. e22.","journal-title":"Cell"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01984-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:06:13Z","timestamp":1771596373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01984-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the Declaration of Helsinki and approved by the Regional Ethical Review Board (Gothenburg, Sweden; case numbers 767\u201314 and 201\u201315, and complementary case numbers T973-15 and T333-16). The patients signed written consent to store their tissue in the regional biobank and be used for research, and the Regional Ethical Review Board approved a waiver of written consent to use the tumor specimens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}